Cargando…
Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects
The prognosis of patients with systemic lupus erythematosus has greatly improved since treatment regimens combining corticosteroids and immunosuppressive medications have been widely adopted in therapeutic strategies given to these patients. Immune suppression is evidently efficient but also leads t...
Autores principales: | Monneaux, Fanny, Muller, Sylviane |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714128/ https://www.ncbi.nlm.nih.gov/pubmed/19591653 http://dx.doi.org/10.1186/ar2711 |
Ejemplares similares
-
Follicular Helper T Cells in Systemic Lupus Erythematosus: Why Should They Be Considered as Interesting Therapeutic Targets?
por: Sawaf, Matthieu, et al.
Publicado: (2016) -
Importance of spliceosomal RNP1 motif for intermolecular T-B cell spreading and tolerance restoration in lupus
por: Monneaux, Fanny, et al.
Publicado: (2007) -
Therapy of systemic lupus erythematosus: a look into the future
por: Smolen, Josef S
Publicado: (2002) -
Disease Progression in MRL/lpr Lupus-Prone Mice Is Reduced by NCS 613, a Specific Cyclic Nucleotide Phosphodiesterase Type 4 (PDE4) Inhibitor
por: Keravis, Thérèse, et al.
Publicado: (2012) -
Cutaneous Lupus Erythematosus: Current and Future Pathogenesis-Directed Therapies
por: Little, Alicia J., et al.
Publicado: (2020)